As PTM seems as the evolving diagnostic and therapeutic stand point in cancer studies (Zhang and Han, 2020; Meng et al., 2021), this study shows the path to think whether these virus-associated cancer types having PTM of PTEN develop mTOR inhibitor drug resistance by mTOR kinase modulation compared to other cancer types with deleted PTEN, which will reveal the therapeutic target point evolution for new-generation mTOR inhibitors to work better in such a cancer setup. The gene discussed is MTOR; the disease is cancer.